He emphasized the strong performance of INGREZZA, which is poised for double-digit year-over-year growth despite moderated expectations compared to 2024, the company’s highest growth year to date.

Neurocrine Biosciences Q4 EPS of $1.69 beat estimates, while revenue missed consensus. Ingrezza sales rose 23% to $615 million. 2025 Ingrezza sales guidance fell short of Street estimate.

INGREZZA Sales Guidance for 2025: $2.5 billion to $2.6 billion, reflecting $250 million growth at the midpoint. CRENESSITY Q4 2024 Sales: $2 million in net sales from initial bottle orders.

William Blair writes that Ingrezza’s 2025 revenue guidance is slightly conservative compared to their 2025 estimate of $2.60 billion and the Street estimate of $2.67 billion, which fell below ...

From a commercial perspective, INGREZZA continues to set the standard. Eight years after introducing the first treatment for tardive dyskinesia, we're on track to once again achieve double-digit ...

Ingrezza fourth quarter and fiscal 2024 net product sales were $615 million and $2.3 billion, respectively. Also Read: Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan ...

FY25 revenue consensus $2.79B. Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock ...

Q4 revenue was $627.7 million, slightly below the $629 million estimate. Ingrezza remains the main revenue driver, with a 23% increase in quarterly sales to $615 million. Neurocrine Biosciences ...

Despite reporting a 26% growth in INGREZZA® (valbenazine) net product sales for the full year of 2024 compared to the previous year, the company's guidance for 2025 disappointed investors.